Trial · NCT07906158
PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis
NCT07906158, Completed, Shengjing Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis. Trials, record NCT07906158. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906158
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis
- NCT number
- NCT07906158
- Status
- Completed
- Enrollment
- 900 participants, actual
- Lead sponsor
- Shengjing Hospital
- Conditions
- Solid Neoplasms, Non-Small Cell Lung Cancer
- Interventions
- This is an observational study with no intervention.
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-Month Progression-Free Survival [PFS] Status | Baseline to 6 months post-treatment initiation | Based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), the risk probability score derived from the baseline 18F-FDG PET/CT multimodal intratumoral heterogeneity model is adopted to predict the binary endpoint of disease progression (PD) or all-cause death within 6 months after patients receive first-line systemic anti-tumor therapy. This binary endpoint evaluates 6 months PFS status in patients. |
| Secondary | Progression-Free Survival | Baseline to progression or death, up to 36 months | Defined as the time interval from the initiation of first-line systemic anti-tumor therapy to the first documented objective disease progression (per RECIST v1.1) or all-cause death. Kaplan-Meier method will be used to plot survival curves. Log-rank test and multivariate Cox proportional hazards regression model will be applied to evaluate the independent prognostic hazard ratio (HR with 95% confidence interval) and C-index (concordance index) of the PET/CT heterogeneity score. |
| Secondary | Overall Survival | Up to 60 months | Defined as the time interval from the date of histopathologically confirmed tumor diagnosis to all-cause death. The independent predictive performance of the PET/CT multimodal model for long-term all-cause mortality risk will be assessed. |
| Secondary | Diagnostic Accuracy for Nodal and Distant Metastases | within 3 months from baseline to post-treatment initiation | Metastasis diagnosis description: Using histopathological biopsy or long-term multimodality imaging combined with follow-up as the reference standard, we will evaluate the diagnostic sensitivity, specificity and area under the ROC curve of baseline PET/CT multimodal metabolic and anatomical features for regional mediastinal lymph node metastasis (N staging) and occult distant organ metastasis (M staging). |
| Other | Objective Response Rate | From treatment initiation to the assessment of best treatment response (usually 2-6 cycles after treatment initiation, approximately 6-18 weeks). | The proportion of patients achieving best objective response (complete response \[CR\] + partial response \[PR\]) and disease control (CR + PR + stable disease \[SD\]) during first-line treatment will be assessed according to RECIST v1.1. The correlation between baseline PET/CT metabolic heterogeneity and short-term treatment response will be analyzed. |
| Other | Disease Control Rate | From treatment initiation to the assessment of best treatment response (usually 2-6 cycles after treatment initiation, approximately 6-18 weeks). | The proportion of patients achieving best objective response (complete response \[CR\] + partial response \[PR\]) and disease control (CR + PR + stable disease \[SD\]) during first-line treatment will be assessed according to RECIST v1.1. The correlation between baseline PET/CT metabolic heterogeneity and short-term treatment response will be analyzed. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906158
GET https://conductscience.org/api/trials/v1/NCT07906158/registered